Abstract Number: 2486 • 2017 ACR/ARHP Annual Meeting
Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)
Background/Purpose: Considering the huge burden of RA in India, the use of biologic DMARDs is miniscule. The major deterrents are cost, poor awareness and few…Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting
Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…Abstract Number: 2488 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Rheumatoid Arthritis. Predictors of Long-Term Retention
Background/Purpose: The efficacy of Golimumab (GLM) treatment in rheumatoid arthritis (RA) has been widely documented. The aim of this study was to analize the long-term…Abstract Number: 2489 • 2017 ACR/ARHP Annual Meeting
Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data
Background/Purpose: According different international registries, around one third of patients under biologic DMARD (bDMARD) with rheumatoid arthritis (RA) are receiving bDMARD as monotherapy (1-4). In…Abstract Number: 2490 • 2017 ACR/ARHP Annual Meeting
Sustained Clinical Response in Refractory Rheumatoid Arthritis Patients with a Low-Dose Rituximab Retreatment Regimen. a Single Center Experience
Background/Purpose: : The standard dose of rituximab (RTX) in rheumatoid arthritis (RA) is two intravenous (iv) 1 g infusions, separated by two weeks. Recently, the…Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting
The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study
Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…Abstract Number: 2493 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA generally receive conventional synthetic DMARDS (csDMARDs)…Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting
Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…Abstract Number: 2495 • 2017 ACR/ARHP Annual Meeting
Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality
Background/Purpose: A biosimilar is a biopharmaceutical product that is highly similar to an already licensed one in terms of quality, safety, and efficacy. We (Samsung…Abstract Number: 2496 • 2017 ACR/ARHP Annual Meeting
The Disease Course in Daily Clinical Practice in Radiographic and Non-Radiographic Axial Spondyloarthritis Patients; One-Year Follow-up Results of National-Subgroup of a Worldwide Observational Cohort Study
Background/Purpose: The natural history of axial spondyloarthritis (axSpA) has not been clearly established yet. The aim of this study is to evaluate the natural course…Abstract Number: 2497 • 2017 ACR/ARHP Annual Meeting
The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Background/Purpose: Spondyloarthritis (SpA) carries substantial financial costs, including direct costs (use of medical services and treatments) and indirect costs (loss of work productivity). While disease…Abstract Number: 2498 • 2017 ACR/ARHP Annual Meeting
Rheumatologists Use Different Cut-Offs for Disease Activity in Real Life – the Experience with Golimumab in Ankylosing Spondylitis- Subanalysis from a Non-Interventional German Study
Background/Purpose: International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) suggest a BASDAI level of disease activity of ≥4 to indicate treatment…Abstract Number: 2499 • 2017 ACR/ARHP Annual Meeting
Gender Differences in Axial and Peripheral Spondyloarthritis: Results from the Esperanza Cohort
Background/Purpose: In patients with spondyloarthritis, published data indicate different manifestations and outcomes between genders. The evidence in this regard in patients with early and peripheral…Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
ACR Meeting Abstracts